Selinexor (KPT-330) is a first in class nuclear transport inhibitor currently in clinical trials as an anti-cancer agent. To determine how selinexor might impact anti-tumor immunity, we analyzed immune homeostasis in mice treated with selinexor and found disruptions in T cell development, a progressive loss of CD8 T cells and increases in inflammatory monocytes. Antibody production in response to immunization was mostly normal. Precursor populations in bone marrow and thymus were unaffected by selinexor, suggesting that normal immune homeostasis could recover. We found that a high dose of selinexor given once per week preserved nearly normal immune functioning, whereas a lower dose given 3 times per week did not restore immune homeostasis. Both naïve and effector CD8 T cells cultured in vitro showed impaired activation in the presence of selinexor. These experiments suggest that nuclear exportins are required for T cell development and function. We determined the minimum concentration of selinexor required to block T cell activation, and showed that T cell inhibitory effects of selinexor occur at levels above 100nM, corresponding to the first 24 hours post-oral dosing. In a model of implantable melanoma, selinexor treatment at 10 mg/kg with a 5 day drug holiday led to intratumoral IFNγ+, granzyme B+ cytotoxic CD8 T cells that were comparable to vehicle treated mice. Overall, selinexor treatment leads to transient inhibition of T cell activation but clinically relevant once and twice weekly dosing schedules that incorporate sufficient drug holidays allow for normal CD8 T cell functioning and development of anti-tumor immunity.
Introduction
Tumor suppressor proteins such as p53 play a key role in genome integrity, and as such are frequently mutated in many types of malignancies (1) . However, many cancers effectively inactivate p53 and other tumor suppressors by upregulation of the exportin XPO1 which shuttles p53 out of the nucleus (2) . XPO1 belongs to a family of proteins called karyopherins which regulate nuclear transport (3) . Importins bind to nuclear localization sequences (NLS) on cargo proteins, translocate to the nucleus where binding of Ran-GTP allows for dissociation of the cargo and recycling of importin to the cytosol. Conversely, exportins such as XPO1 bind Ran-GTP and nuclear export sequences (NES) on cargo proteins inside the nucleus and are transported out of the nucleus (3) (4) (5) . XPO1 facilitates transport of approximately 200 cargo proteins, including the tumor suppressor proteins p53, BRCA, IκB, p21, and FOXO (6) . XPO1 also shuttles eukaryotic initiation factor 4e (eIF4e), which transports guanine capped mRNAs, including those encoding key oncogenes, into the cytosol (7) . Enhanced XPO1 activity results in removal of p53 from the nucleus and increased transcript levels of myc, cyclin D1, and MDM2 (7). XPO1 is overexpressed or correlates with poor prognosis in many tumor types including glioma, osteosarcoma, pancreatic, gastric, ovarian, and cervical cancers highlighting the importance of nuclear transport to maintaining the non-transformed state (8) (9) (10) (11) (12) (13) (14) .
Selective inhibitors of nuclear export (SINE) compounds have been developed. Selinexor (KPT-330) is a highly specific, slowly reversible, covalent inhibitor of XPO1, and has shown promising results in phase I/II clinical trials of hematologic and solid malignancies (15) (16) (17) . Selinexor treatment dramatically reduces tumor burden in a variety of both xenograft and syngeneic mouse models (18) (19) (20) (21) (22) (23) . Although selinexor is fairly well tolerated, side effects of treatment include fatigue, nausea and thrombocytopenia (17) .
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Selinexor traps all XPO1 target proteins in the nucleus, which includes several transcription factors or transcription factor regulators that play critical roles in immune system function: NFATc1, IκBα, p100 and p65 (subunits of NF-κB), cIAP1, STAT1 and STAT3 (6) . Although transcription factors bind DNA in the nucleus, many transcription factors require dimerization, phosphorylation, ligand binding, or proteolytic degradation of an inhibitory protein for their activity. Many of these events occur in the cytosol, thus inhibition of XPO1 can constitutively trap transcription factors in either active or inactive forms. STAT1 activity is transiently enhanced by nuclear localization, but inhibition of nuclear export of STAT1 results in diminished ability of cells to upregulate transcription of IFNγ responsive genes (24). STAT3 is transported to the nucleus in its inactive conformation in non-cytokine stimulated cells, and addition of the XPO1 inhibitor leptomycin B leads to the accumulation of inactive STAT3 in the nucleus (25).
NF-κB becomes trapped in the nucleus along with its inhibitor IκBα, leading to abrogation of activity upon treatment with selinexor or leptomycin B (5, (26) (27) (28) . Other proteins of immunologic interest that rely on XPO1 for nuclear export include fyn, AID, AHR, and DGKζ, although it is unclear how loss of XPO1 function would affect the activity of these targets (21).
The immune system is important for both controlling infection and in generation of anti-tumor immunity. Cytotoxic T cells, in particular, correlate with increased overall survival in colorectal and other cancers (29) . Immunotherapy has shown impressive clinical benefit, particularly for metastatic melanoma. The FDA has approved four immune-modulating drugs that target T cell inhibitory pathways, ipilimumab (anti-CTLA-4), nivolumab/pembrolizumab (anti-PD-1) and atezolizumab (anti-PD-L1) (30-33). Since immunotherapy targets the immune system, and not a particular type of cancer, these new drugs were originally hoped to be applicable across all tumor types as a pan-cancer medication. Indeed, significant clinical results have been seen for 5 ipilimumab or PD-1 blockade in non-small cell lung cancer, renal cell cancer, castration-resistant prostate cancer, Hodgkin's lymphoma, and multiple cancer types deficient in mismatch repair (31, 32, 34, 35) . The clinical success of monoclonal antibodies targeting negative regulators on T cells demonstrates that a significant fraction of cancer patients have anti-tumor T cells at baseline, and that manipulating these T cells can have therapeutic benefit. Naïve tumor-specific T cells must be primed by dendritic cells presenting antigens released from dying tumor cells. This priming stage is necessary for expansion of tumor-specific clones and for acquisition of effector functions such as cytotoxicity and cytokine production. T cell priming is enhanced by dying tumor cells which release both antigens and endogenous danger signals such as HMGB1 or 2'3'cGAMP, which can activate dendritic cells to enhance antigen presentation, expression of costimulatory molecules, and trafficking to the tumor draining lymph node (36, 37). Therapies that kill tumor cells would be predicted to enhance T cell priming and synergize with immunotherapy, and indeed this has been the case for radiation (38, 39) , chemotherapy (36, 40) and some targeted therapies (41, 42) .
The general ability of most conventional therapies to enhance response to immunotherapy has led to a flurry of combination clinical trials. Immunotherapy has the potential for durable longterm remissions; however, the fraction of patients who respond is relatively low for most cancer types. Combination therapy is likely necessary to extend the benefit of immunotherapy to more patients. Although general consensus and support for combination therapy exists, most standard cancer therapies have not been evaluated for their effects on the immune system, or those effects have been equivocal. For example, radiation releases tumor antigens (39) , but also stimulates radiation-resistant mesenchymal stem cells which can cause local immunosuppression and make irradiated bone marrow a preferred metastatic niche (43) .
Chemotherapies kill rapidly dividing cells, with certain agents preferentially eliminating Tregs 6 (44), MDSCs (45, 46) , or even proliferating CD8 T cells (47) . A better understanding of the effects of various cancer treatments on cells of the immune system is important for making rationally designed combination strategies.
Here we examined the effects of selinexor on normal immune homeostasis in mice, and recapitulated a side effect profile similar to that seen in humans. We further showed that naïve and effector CD8 T cells were inhibited by selinexor, but only at high concentrations and for a short time window. We show that decreased frequency of selinexor dosing greatly mitigates these effects, and we successfully predicted a regimen of selinexor dosing that allows for simultaneous development of robust anti-tumor immunity. These findings illustrate a simple preclinical method for assessing novel chemotherapies in combination with immunotherapy using established murine models.
Materials and Methods
Animal care: All animals were housed at Dana-Farber Cancer Institute and were maintained according to protocols approved by the DFCI IACUC Committee on Animal Care. C57BL/6 and OT-I;RAG1-/-mice were purchased from Jackson Labs. TRP1high;CD45.1 mice were bred in house (48) . Flow cytometry: Cells were harvested from spleen, mesenteric lymph nodes, bone marrow or thymus. Tissues were crushed into PBS through a 40 micron cell strainer using the back of a 1 mL syringe plunger. Cell preparations were subjected to hypotonic lysis to remove erythrocytes, stained and analyzed using a Fortessa (BD). CD1d(PBS57) tetramer was obtained from the NIH Cell culturing: Cells were cultured in RPMI 1640 medium supplemented with 10% heatinactivated FBS, 2 mM l-glutamine, 100 U/ml penicillin G sodium, 100 μg/ml streptomycin sulfate, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 0.1 mM 2-ME. CD8 T cells were isolated from pooled spleen and LNs of TRP1high;CD45.1, OT-I:RAG1-/-or wild type mice using positive selection on anti-CD8 magnetic beads (Dynabeads, Invitrogen). For generation of effector CD8T cells, isolated naïve CD8 T cells were plated into 12 well dishes at 1 million cells per mL with anti-CD3/CD28 beads (Invitrogen) and 100 U/mL recombinant human IL-2 (Peprotech). Beads were removed after 48 hours, and fresh IL-2 containing media was added every two to three days. T cells were cultured for 7 days prior to washing, counting, and plating into 24 well dishes containing B16 cells or B16 that had been transduced with ovalbumin (B16OVA) cells that had been pre-treated for 24 hours with recombinant mouse IFNγ (10ng/mL) (Peprotech) to induce upregulation of surface MHC class I. 200,000 T cells were added per well. Naïve T cell activation assays: CD8 T cells were isolated using positive selection as described Statistics: Student's t test was used to compare means. Error bars are SD throughout.
Results

Selinexor affects normal immune homeostasis, with the greatest effect on CD8 T cells
To determine the effects of selinexor on normal immune homeostasis, we treated mice orally with vehicle control or selinexor at 15 mg/kg three times per week (M,W,F). Mice were treated for one week, two weeks, or four weeks and thymus, bone marrow, and spleen populations were analyzed. A striking loss of thymus cellularity was evident ( Figure 1A We next examined the bone marrow of vehicle control or 28 day selinexor treated mice.
Hematopoietic stem cells, contained within the lineage negative fraction, were not obviously inhibited by selinexor treatment as total cellularity of the bone marrow was maintained, and most populations of cells appeared to be present. We observed a striking absence of CD8 T cells in the bone marrow, as well as an apparent block in B cell development with more B cells stuck in the earlier pro and pre B cell stages of development and fewer immature B cells in selinexor treated mice ( Figure 1E ). In the spleen we observed a progressive loss of CD8 T cells over time, with a concomitant increase in monocytes ( Figure 1F ).
Selinexor treatment only modestly affects antibody production
One of the target proteins of XPO1 is activation induced deaminase (AID), an enzyme critical for B cell isotype switching and affinity maturation. Without AID function, high affinity IgGs cannot be produced. To investigate AID function in the context of selinexor treatment, we immunized mice with a model antigen ovalbumin and measured ovalbumin specific antibody production over time (Figure 2A ). One week post-immunization, all three vehicle control treated mice had measureable anti-ovalbumin antibodies while the selinexor treated mice were indistinguishable from non-immunized controls ( Figure 2B ). By two weeks post-immunization, this difference was no longer apparent; all selinexor mice showed high titer anti-ovalbumin antibodies at the two week and later time points that were equivalent to vehicle control treated mice. When IgG1, IgG2b, IgG2c, and IgA isotypes were analyzed, we again saw negligible differences in antigenspecific IgG1 and IgA, although mild deficiencies in antigen-specific IgG2b and IgG2c were noted. Subtle differences in affinity or clonal diversity would not be detected by the ELISA assay used. Serum IFNγ levels were similar between the two groups, as were the numbers of CD4+ T follicular helper cells generated (Supplemental Figure 1) . The slight delay in antibody production could indicate a transient block in BCR signaling; this observation combined with the block in B cell development in the bone marrow ( Figure 1E ) suggests that further study of the effects of selinexor on both malignant and normal B cells may be warranted. However, the presence of antigen-specific class-switched antibody demonstrates that AID must be functional.
Decreasing the frequency, but not the dose of selinexor, restores normal immune homeostasis Given that the lineage negative cells in the bone marrow, and DN populations in the thymus, were unaffected by even prolonged 28 days of selinexor treatment, we predicted that precursor populations would be intact and able to restore normal population levels in bone marrow, thymus and secondary lymphoid organs after drug withdrawal. Based on preclinical assessment in a variety of tumor models, 15 mg/kg dosed three times per week is a relatively high dose of selinexor, and anti-tumor function is still observed at doses as low as 6 mg/kg (data not shown).
We therefore investigated immune populations in mice dosed for 4 weeks according to the schedule shown in Figure 3A . The 15x3 group received exactly the same dose regimen as mice shown in Figure 1 , and again we found profound loss of thymic cellularity, loss of CD8 T cells and immature B cells from the bone marrow, and loss of CD8 T cells and compensatory increases in inflammatory monocytes in the secondary lymphoid organs ( Figure 3B -E).
Our two experimental groups were mice that received one high dose of selinexor (15x1) versus mice that received a low dose of selinexor three times per week (7.5x3). As clearly evident, mice in the 15x1 group were similar to the vehicle controls while mice in the 7.5x3 group were indistinguishable from the 15x3 group ( Figure 3B-E ). These data demonstrate that decreasing the frequency of selinexor dosing has a much more favorable impact on immune homeostasis than decreasing the actual dose given.
Selinexor blocks TCR signaling in naïve T cells
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Of all of the populations examined, CD8 T cells were most sensitive to selinexor treatment (Figures 1 and 3) . Given the importance of CD8 T cells to anti-tumor immunity, we wanted to examine the effects of selinexor on CD8 T cell function in more detail. Naïve CD8 T cells were 
Discussion
Selinexor alters the nuclear localization of some 200 proteins that rely on XPO1 for export from the nucleus. Several of these XPO1 cargos are absolutely required for immune cell development and function. We found that T cells, most notably CD8 T cells, were sensitive to selinexor treatment. In vivo, selinexor dosing caused dramatic reductions in thymocyte numbers, and a progressive loss of CD8 T cells from bone marrow, spleen and lymph nodes.
Naïve CD4 and CD8 T cells were refractory to activation in the presence of selinexor. Effector CD8 T cells, despite no longer requiring costimulation, were also blocked in their capacity to degranulate or produce IFNγ when selinexor was present. Although we do not identify the exact proteins whose improper nuclear localization causes these effects on T cells, we suspect that several players contribute, including NF-κB, a heterodimeric transcription factor that is 
